First National Trust Co increased its position in Bristol-Myers Squibb Co (NYSE:BMY) by 65.7% in the first quarter, Holdings Channel reports. The institutional investor owned 87,990 shares of the biopharmaceutical company’s stock after acquiring an additional 34,902 shares during the period. First National Trust Co’s holdings in Bristol-Myers Squibb were worth $4,198,000 at the end of the most recent quarter.
Several other large investors have also recently bought and sold shares of the company. Financial Gravity Wealth Inc. purchased a new stake in Bristol-Myers Squibb in the first quarter valued at approximately $26,000. Capital Financial Planning LLC purchased a new stake in Bristol-Myers Squibb in the fourth quarter valued at approximately $28,000. Well Done LLC purchased a new stake in Bristol-Myers Squibb in the fourth quarter valued at approximately $30,000. Trust Department MB Financial Bank N A purchased a new stake in Bristol-Myers Squibb in the first quarter valued at approximately $32,000. Finally, Riverview Trust Co purchased a new stake in Bristol-Myers Squibb in the fourth quarter valued at approximately $33,000. 74.09% of the stock is owned by institutional investors and hedge funds.
BMY opened at $46.85 on Friday. The company has a quick ratio of 1.79, a current ratio of 1.93 and a debt-to-equity ratio of 0.37. Bristol-Myers Squibb Co has a 52-week low of $44.30 and a 52-week high of $63.69. The company has a market cap of $77.07 billion, a price-to-earnings ratio of 11.77, a price-to-earnings-growth ratio of 2.20 and a beta of 0.77.
The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, May 1st. Shareholders of record on Friday, April 5th were paid a dividend of $0.41 per share. The ex-dividend date of this dividend was Thursday, April 4th. This represents a $1.64 annualized dividend and a yield of 3.50%. Bristol-Myers Squibb’s dividend payout ratio is currently 41.21%.
A number of equities research analysts recently issued reports on the stock. Zacks Investment Research upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $60.00 target price for the company in a report on Tuesday, March 5th. BMO Capital Markets restated a “buy” rating and issued a $59.00 target price on shares of Bristol-Myers Squibb in a report on Tuesday, February 19th. Credit Suisse Group restated a “hold” rating and issued a $59.00 target price on shares of Bristol-Myers Squibb in a report on Friday, February 15th. Bank of America lowered their target price on shares of Bristol-Myers Squibb from $53.00 to $51.00 and set a “neutral” rating for the company in a report on Tuesday, February 19th. Finally, ValuEngine upgraded shares of Bristol-Myers Squibb from a “strong sell” rating to a “sell” rating in a report on Saturday, May 4th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and eight have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $57.64.
TRADEMARK VIOLATION NOTICE: This article was reported by WKRB News and is the sole property of of WKRB News. If you are viewing this article on another website, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this article can be viewed at https://www.wkrb13.com/2019/05/19/first-national-trust-co-has-4-20-million-stake-in-bristol-myers-squibb-co-bmy.html.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
Read More: What is a resistance level?
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.